Antiepileptic drugs | Clinical drug development in epilepsy

Sills, G.J. and Brodie, M.J. (2009) Antiepileptic drugs | Clinical drug development in epilepsy. In: Schwartzkroin, P. A. (ed.) Encyclopedia of Basic Epilepsy Research. Elsevier: Amsterdam, pp. 1477-1485. ISBN 9780123739612 (doi: 10.1016/B978-012373961-2.00033-3)

Full text not currently available from Enlighten.


Clinical drug development in epilepsy is characterized by a succession of trials with the principal aim of bringing a new compound to market. This article reviews the development process from first human exposure through regulatory approval to postmarketing evaluation. The basic principles of clinical trial design are examined and their application – in Phase I studies in healthy volunteers and in Phase II and Phase III studies in epilepsy patients – discussed. Monotherapy studies, the differing requirements of individual regulatory authorities, and the limitations of antiepileptic drug trials – particularly with regard to their ability to inform everyday clinical practice – are also considered.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Sills, Dr Graeme
Authors: Sills, G.J., and Brodie, M.J.
College/School:College of Medical Veterinary and Life Sciences > School of Life Sciences

University Staff: Request a correction | Enlighten Editors: Update this record